Table 1.
Baseline characteristics of patients
| Variables | Total (N = 9534) |
NRE (n = 2730) |
RE (n = 6804) |
P value |
|---|---|---|---|---|
| Age: years | 60.4 ± 11.1 | 61.6 ± 10.8 | 59.9 ± 11.1 | < 0.001 |
| Male: n (%) | 6692 (70.2) | 1888 (69.2) | 4804 (70.6) | 0.170 |
| BMI: kg/m2 | 25.1 ± 3.8 | 24.9 ± 3.4 | 25.3 ± 3.9 | < 0.001 |
| Current smoker: n (%) | 4100 (43.0) | 1038 (38.0) | 3062 (45.0) | < 0.001 |
| Urban: n (%) | 5657 (59.3) | 1447 (53.0) | 4210 (61.9) | < 0.001 |
| Educational attainment | < 0.001 | |||
| Primary school or below: n (%) | 3212 (33.7) | 1164 (42.6) | 2048 (30.1) | |
| Junior high school: n (%) | 2921 (30.6) | 840 (30.8) | 2081 (30.6) | |
| High school or vocational college: n (%) | 2075 (21.8) | 471 (17.3) | 1604 (23.6) | |
| University graduation or higher: n (%) | 1326 (13.9) | 255 (9.3) | 1071 (15.7) | |
| Economic status | < 0.001 | |||
| Low: n (%) | 5372 (56.3) | 1821 (66.7) | 3551 (52.2) | |
| Medium: n (%) | 2747 (28.8) | 636 (23.3) | 2111 (31.0) | |
| High: n (%) | 1415 (14.8) | 273 (10.0) | 1142 (16.8) | |
| Diagnosis | < 0.001 | |||
| STEMI: n (%) | 5052 (53.0) | 1168 (42.8) | 3884 (57.1) | |
| NSTEMI: n (%) | 2776 (29.1) | 719 (26.3) | 2057 (30.2) | |
| UA: n (%) | 1706 (17.9) | 843 (30.9) | 863 (12.7) | |
| Past medical history | ||||
| Hypertension: n (%) | 4954 (52.0) | 1372 (50.3) | 3582 (52.6) | 0.035 |
| Hyperlipidemia: n (%) | 6273 (65.8) | 1693 (62.0) | 4580 (67.3) | < 0.001 |
| Diabetes mellitus: n (%) | 3084 (32.3) | 843 (30.9) | 2241 (32.9) | 0.052 |
| Previous MI: n (%) | 1068 (11.2) | 383 (14.0) | 685 (10.1) | < 0.001 |
| Family history of CHD: n (%) | 2587 (27.1) | 544 (19.9) | 2043 (30.0) | < 0.001 |
| Previous PCI: n (%) | 1268 (13.3) | 608 (22.3) | 660 (9.7) | < 0.001 |
| Previous CABG: n (%) | 26 (0.3) | 16 (0.6) | 10 (0.1) | < 0.001 |
| Previous stroke: n (%) | 1765 (18.5) | 520 (19.0) | 1245 (18.3) | 0.394 |
| Previous HF: n (%) | 221 (2.3) | 82 (3.0) | 139 (2.0) | 0.005 |
| CKD: n (%) | 1554 (16.3) | 465 (17.0) | 1089 (16.0) | 0.219 |
| Laboratory test | ||||
| cTnI: μg/L | 19.9 (2.4–72.0) | 8.5 (0.4–57.5) | 24.6 (4.8–78.3) | < 0.001 |
| CK-MB: μg/L | 60.2 (4.8–192.0) | 20.0 (1.5–139.4) | 80.0 (9.3–208.2) | < 0.001 |
| BNP: pg/mL | 958.5 (293.2–2556.0) | 963.0 (244.0–2556.0) | 955.0 (310.0–2473.2) | 0.920 |
| TC: mg/dL | 176.5 ± 42.4 | 171.9 ± 42.2 | 178.4 ± 42.3 | < 0.001 |
| TG: mg/dL | 128.3 (88.5–168.2) | 132.8 (89.4–168.2) |
126.6 (87.6–168.2) |
0.087 |
| LDL-C: mg/dL | 110.5 ± 35.8 | 105.4 ± 35.3 | 112.6 ± 35.7 | < 0.001 |
| HDL-C: mg/dL | 45.8 ± 11.0 | 45.5 ± 11.2 | 45.9 ± 11.0 | 0.134 |
| Scr: μmol/L | 81.0 (69.0–94.0) | 81.0 (69.0–94.0) | 81.0 (69.0–94.0) | 0.958 |
| BUN: mmol/L | 5.7 (4.6–7.0) | 5.8 (4.7–7.1) | 5.7 (4.6–6.9) | 0.009 |
| Hs-CRP: mg/dL | 5.2 (2.0–11.1) | 4.8 (1.7–10.4) | 5.3 (2.1–11.3) | < 0.001 |
| HbA1C: % | 6.4 ± 1.3 | 6.5 ± 1.3 | 6.4 ± 1.3 | 0.191 |
| LVEF: % | 57.4 ± 7.5 | 57.4 ± 7.5 | 57.3 ± 7.5 | 0.662 |
| Medications history | ||||
| Aspirin: n (%) | 1968 (20.6) | 568 (20.8) | 1400 (20.6) | 0.802 |
| P2Y12 receptor inhibitors: n (%) | 614 (6.4) | 187 (6.8) | 427 (6.3) | 0.302 |
| Statins: n (%) | 936 (9.8) | 281 (10.3) | 655 (9.6) | 0.323 |
| Beta blocker: n (%) | 680 (7.1) | 177 (6.5) | 503 (7.4) | 0.119 |
| ACEI/ARB: n (%) | 511 (5.4) | 138 (5.1) | 373 (5.5) | 0.403 |
| Medications at discharge | ||||
| Aspirin: n (%) | 9284 (97.4) | 2554 (93.6) | 6730 (98.9) | < 0.001 |
| P2Y12 receptor inhibitors: n (%) | 9323 (97.8) | 2554 (93.6) | 6769 (99.5) | < 0.001 |
| Statins: n (%) | 9231 (96.8) | 2510 (91.9) | 6721 (98.8) | < 0.001 |
| Beta blocker: n (%) | 5633 (59.1) | 1387 (50.8) | 4246 (62.4) | < 0.001 |
| ACEI/ARB: n (%) | 4325 (45.4) | 983 (36.0) | 3342 (49.1) | < 0.001 |
| Medications at follow-up | ||||
| Aspirin: n (%) | 8990 (94.3) | 2425 (88.8) | 6565 (96.5) | < 0.001 |
| P2Y12 receptor inhibitors: n (%) | 8583 (90.0) | 2058 (75.4) | 6525 (95.9) | < 0.001 |
| Statins: n (%) | 8988 (94.3) | 2355 (86.3) | 6633 (97.5) | < 0.001 |
| Beta blocker: n (%) | 5439 (57.0) | 1155 (42.3) | 4284 (63.0) | < 0.001 |
| ACEI/ARB: n (%) | 4027 (42.2) | 733 (26.8) | 3294 (48.4) | < 0.001 |
Data are presented as mean ± SD: median (interquartile range): or number (%)
Low economic status: defined as an average monthly income per person of less than 2,500 RMB. Medium economic status: defined as an average monthly income per person between 2,500 and 5,000 RMB. High economic status: defined as an average monthly income per person of 5,000 RMB or more
BMI body mass index, UA unstable angina, NSTEMI non-ST segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, MI myocardial infarction, CHD coronary heart disease, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, HF heart failure, CKD chronic kidney disease, cTNI cardiac troponin I, CK-MB creatine kinase-MB, BNP B-type natriuretic peptide, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, Scr serum creatinine, BUN blood urea nitrogen, Hs-CRP hypersensitive C-reactive protein, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, RE reexamination, NRE non-reexamination